Search
Skip to Search Results- 1Chaurasiya, Shyambabu
- 1Fung, Rachel D
- 1Gupta, Nancy
- 1Irwin, Chad Robert
- 1Mohamed, Adil SG
- 1Molavi, Ommoleila
-
Combination Radiation Therapy and Oncolytic Vaccinia Virus Therapy in Preclinical Models of Glioma
DownloadSpring 2017
Gliomas are the most common primary malignant brain tumour in adults, with glioblastoma multiforme (GBM), the most common and most deadly form of glioma, making up over half of all diagnosed cancers in the brain/central nervous system. The standard of care for gliomas has remained unchanged for...
-
Deletion of F4L (ribonucleotide reductase) in Vaccinia Virus Produces a Selective Oncolytic Virus and Promotes Anti-tumor Immunity with Superior Safety in Bladder Cancer
DownloadFall 2017
Overall recurrence of non-muscle-invasive bladder cancer (NMIBC) can be as high as 80% within 5 years of initial treatment. High-grade NMIBC has the greatest risk of recurrence and treatment for these patients includes surgery followed by intravesical therapy with the immunotherapeutic agent...
-
Delivery of STAT3 inhibitor cucurbitacins to tumor by polymeric nano-carriers : Implications in cancer chemo- and immunotherapy
DownloadFall 2009
Signal Transducer and Activator of Transcription 3 (STAT3), a common oncogenic mediator, is constitutively activated in many types of human cancers and plays a critical role in tumor growth and cancer immune evasion. The focus of this dissertation is the delivery of STAT3 inhibitor cucurbitacins...
-
Fall 2018
Mammalian orthoreovirus (reovirus) is a non-pathogenic virus that naturally infects through the enteric and respiratory routes. Reoviruses are non-enveloped and have a 10-segment double stranded RNA (dsRNA) genome encased in 2 concentric capsid shells. Representative isolates of each of the 3...
-
Spring 2021
Vaccinia virus (VACV) has shown promise as an oncolytic agent for treating a variety of tumour types, with preliminary results suggesting that this strategy holds promise for treating breast cancer. Our lab has previously modified VACV by deleting virally-encoded enzymes responsible for dNTP...
-
Investigating Radiation in Combination with Oncolytic Vaccinia Virus to Improve the Treatment of Glioblastoma
DownloadFall 2023
Glioblastoma (GBM) is a malignant and immune-suppressed brain cancer that remains incurable despite the current standard of care. Radiotherapy is a mainstay of GBM treatment, however invasive cancer cells outside the irradiated field and radioresistance preclude complete eradication of GBM cells....
-
Investigations into Differences between Vaccinia and Myxoma Virus Plaquing Properties Identifies Strategies for Increasing the Oncolytic Efficacy of Myxoma Virus
DownloadFall 2013
Despite both being poxviruses, vaccinia (VACV) and myxoma (MYXV) form very different plaque types. VACV plaques are large and show a central clearing of cells, while MYXV plaques are smaller and result in a clumping of cells. VACV spread is promoted by the formation of an enveloped form of virus...
-
Novel Agents Inhibiting Hepatitis C Virus; Application to Prevention of Re-infection after Liver Transplantation
DownloadFall 2013
Recurrent Hepatitis C virus infection drives inferior outcomes experienced by patients undergoing liver transplantation due to HCV-associated liver disease. Existing therapies exhibit increased toxicity, poor efficacy, and profound patient intolerability in the immediate transplantation period....
-
Spring 2017
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), continues to be a leading infectious cause of death worldwide with approximately 10 million new cases and 2 million deaths attributed annually. There has been resurgence in active TB infections since 1980s and the World Health...